# *Supplementary Material*

## 1 Supplementary Table

**Table S1.** Treatment groups and their corresponding supernatant dilutions derived from PBMCs

| Treatment Groups (Short forms) | Description |
|---|---|
| VC | Virus control refers to untreated Huh-7 or A549 cells infected with virus at an MOI of 0.1. |
| Neg Sup 1:10 | 10-fold diluted supernatant derived from PBMCs (without treatment, Negative control) |
| CpG Sup 1:10 | 10-fold diluted supernatant derived from 1 μM of CpG ODN 2216-stimulated PBMCs |
| LCP Sup 1:10 | 10-fold diluted supernatant derived from 10 μg/mL of LC-Plasma-stimulated PBMCs |
| LCP Sup 1:100 | 100-fold diluted supernatant derived from 10 μg/mL of LC-Plasma-stimulated PBMCs |
| LCP Sup 1:1000 | 1000-fold diluted supernatant derived from 10 μg/mL of LC-Plasma-stimulated PBMCs |
| LCP Sup 1:5 | 5-fold diluted supernatant derived from 10 μg/mL of LC-Plasma-stimulated PBMCs |
| LCP Sup 1:15 | 15-fold diluted supernatant derived from 10 μg/mL of LC-Plasma-stimulated PBMCs |